Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (98)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (5)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (297)
  2. Department of Medicine (297)
  3. Hematologic Malignancies, Division of (297)
  4. Myeloma (297)
  5. Survivorship Research (216)
  6. Hematologic Malignancies Research (212)

More Groups

People
  1. Neha Korde (191)
  2. Alexander Lesokhin (170)
  3. Hani Hassoun (163)
  4. Sergio Giralt (161)
  5. Malin Hultcrantz (158)
  6. Heather Landau (147)

More People

Years
  1. 2025 (13)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (96)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. Blood Cancer Journal (12)
  5. JAMA Oncology (12)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (107)
  2. Elsevier Inc. (71)
  3. Nature Publishing Group (26)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (297)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hematological count recovery in patients undergoing treatment with chimeric antigen receptor T cells (CAR T)
    Meeting Abstract

    Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Maloy, M. A.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Using current clinical markers to define high risk smoldering multiple myeloma: Agree to disagree
    Meeting Abstract

    Hill, E.; Korde, N.; Mailankody, S.; Morrison, C.; Dew, A.; Albert, J. H.; Graap, K.; Maura, F.; Landgren, O.; Kazandjian, D.
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • FDA analysis: Impact of body mass index (BMI) on outcomes in relapsed-refractory multiple myeloma
    Meeting Abstract

    Ershler, R.; Kanapuru, B.; Gong, Y.; Shah, U. A.; Mailankody, S.; Landgren, O.; Theoret, M.; Gormley, N. J.; Farrell, A. T.; Pazdur, R.
    Blood (2019)

    Fulltext@MSK | Save
  • MALDI-TOF mass spectrometry in serum for the follow-up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Meeting Abstract

    Eveillard, M.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Smith, E. L.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Korde, N.; Landgren, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy
    Meeting Abstract

    Smith, M.; Littmann, E.; Slingerland, J.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Peled, J. U.; Park, J.; O'Cearbhaill, R.; Mailankody, S.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft purity with novel induction regimens in multiple myeloma
    Meeting Abstract

    Bal, S.; Landau, H.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Hassoun, H.; Hultcrantz, M.; Korde, N. S.; Lesokhin, A. M.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Many shades of disparities in myeloma care
    Review

    Ganguly, S.; Mailankody, S.; Ailawadhi, S.
    American Society of Clinical Oncology Educational Book (2019)

    Fulltext@MSK | Save